Affiliation:
1. Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences , Bratislava , Slovak Republic
2. Department of Pharmacology, Jessenius Faculty of Medicine , Comenius University , Martin , Slovak Republic
Abstract
Abstract
At present, affective disorders are among the most commonly diagnosed mental diseases. In pregnancy, they can occur as pre-delivery depression, recurrent depressive disorder or postnatal depression. The estimated prevalence of depressive disorders in pregnancy is approximately 9–16%, with some statistics reporting up to 20%. Approximately 2–3% of pregnant women take antidepressants during pregnancy, and the number of mothers treated increases by birth to 5–7%. Treatment of depression during pregnancy and breastfeeding is a controversial issue, as antidepressants can negatively affect the developing fetus. According to epidemiological studies, the effects of treated depression in pregnancy are related to premature birth, decreased body weight of the child, intrauterine growth retardation, neonatal adaptive syndrome, and persistent pulmonary hypertension. However, untreated depression can adversely affect maternal health and increase the risk of preeclampsia and eclampsia, as well as of subsequent postnatal depression, which can lead to disruption of the mother-child relationship. Based on the above mentioned facts, the basic question arises as to whether or not to treat depression during pregnancy and lactation.
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology
Reference53 articles.
1. Addis A, Koren G. (2000). Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med30: 89–94.10.1017/S0033291799001270
2. Başterzi AD, Yazici K, Aslan E, Delialioğlu N, Taşdelen B, Tot Acar S, Yazici A. (2009). Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry33: 281–5.10.1016/j.pnpbp.2008.11.016
3. Bruschettini M, van den Hove DL, Gazzolo D, Bruschettini P, Blanco CE, Stein-busch HW. (2005). A single course of antenatal betamethasone reduces neurotrophic factor S100B concentration in the hippocampus and serum in the neonatal rat. Brain Res Dev Brain Res159: 113–8.
4. Clarke C, Clarke K, Muneyyirci J, Azmitia E, Whitaker-Azmitia PM. (1996). Prenatal cocaine delays astroglial maturation: immunodensitometry shows increased markers of immaturity (vimentin and GAP-43) and decreased proliferation and production of the growth factor S-100. Brain Res Dev Brain Res91: 268–73.10.1016/0165-3806(95)00192-1
5. da-Silva VA, Altenburg SP, Malheiros LR, Thomaz TG, Lindsey CJ. (1999). Post-natal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Brazilian J Med Biol Res32: 93–8.
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献